Biochemical markers preterm labor and birth: What is their role in the care of pregnant women?

MCN The American Journal of Maternal Child Nursing

Volumn 24, Issue 2, 1999, Pages 80-86

  Moore, Mary Lou ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Labor onset; Labor, premature; Markers, biochemical; Pregnancy

Indexed keywords

BIOLOGICAL MARKER; ESTRIOL; FETOPROTEIN; FIBRONECTIN;

CHEMISTRY; COMPARATIVE STUDY; ECONOMICS; FEMALE; HUMAN; LABORATORY DIAGNOSIS; MASS SCREENING; METABOLISM; METHODOLOGY; PREGNANCY; PREMATURE LABOR; REPRODUCIBILITY; REVIEW; SALIVA; SECOND TRIMESTER PREGNANCY; SENSITIVITY AND SPECIFICITY; THIRD TRIMESTER PREGNANCY; UTERINE CERVIX MUCUS;

BIOLOGICAL MARKERS; CERVIX MUCUS; ESTRIOL; FEMALE; FETAL PROTEINS; FIBRONECTINS; HUMANS; MASS SCREENING; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; REPRODUCIBILITY OF RESULTS; SALIVA; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING;

EID: 0033088799     PISSN: 0361929X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005721-199903000-00007     Document Type: Article

References (25)

1. Bittar, A., Yamasaki, A., Sasaki, S., & Zugaib, M. (1996). Cervical fetal fibronectin in patients at increased risk for preterm delivery. American Journal of Obstetrics and Gynecology, 174, 178-181.
2. Dunn, P., & Feinberg, R. (1996). Oncofetal fibronectin; New insight into the physiology of implantation and labor. Journal of Obstetric, Gynecologic, and Neonatal Nursing, 25, 753-757.
3. Feinberg, R., Kliman, H., Bedian, V., Monzon-Bordonaba, E., Menzin, A., & Wang, C (1995). Monoclonal antibody X18A4 identifies an oncofetal fibronectin epitope distinct from the FDC-6 binding site. American Journal of Obstetrics and Gynecology, 172, 1526-1536.
4. Feinberg, R., Kliman, H., & Lockwood, C. (1991). Is oncofetal fibronectin a trophoblast glue for human implantation? American Journal of Pathology, 138, 537-543.
5. Gardner, M., Rouse, D., & Joffe, G. (1998). Cost-benefit analysis of fetal fibronectin screening. American Journal of Obstetrics and Gynecology, 178, S121.
6. Giles, W., Knox, G., Madsen, G., Bisits, A., & Smith, R. (1998). The effect of fetal fibronectin usage on admissions to a tertiary maternal fetal medicine unit and cost savings. American Journal of Obstetrics and Gynecology, 178, S121.
7. Hedriana, H., Siobhan, P., & Gilbert, W. (1996). Clinical correlation of salivary estriol concentration and cervical ripening: a possible role for fetal estriol in the onset of parturition. American Journal of Obstetrics and Gynecology, 174, 481, #631.
8. Hellemans, P., Cerris, J., & Verdon, K. (1995). Fetal fibronectin detection for prediction of preterm birth in low risk women. British Journal of Obstetrics and Gynaecology, 102, 207-212.
9. Hendershott, C., Dullien, V., & Goodwin, T. (1996). Serial betamethasone administration and effect on maternal salivary estriol levels. Journal of Society for Gynecologic Investigation, 3, 2(Supplement), #276.
10. Iams, J., Casal, D., McGregor, J., Goodwin, T., Kreaden, V., & Lowensohn, R. (1995). Fetal fibronectin improves the accuracy of diagnosis of preterm labor. American Journal of Obstetrics and Gynecology, 173, 141-145.
11. Jackson, G., McGregor, J., Lachelin, G., Goodwin, T., Artal, R., & Dullien, V. (1995). Salivary estriol rise predicts preterm labor. American Journal of Obstetrics and Gynecology, 172, 406.
12. Joffe, G., Jacques, D., Burton, B., Bemis-Heys, R., & Shelbume, P. (1998). Impact of fetal fibronectin assay on admissions for preterm labor. American Journal of Obstetrics and Gynecology, 178, S11.
13. Lockwood, C. J., Senyei, A., Dische, R., Casal, D., Shah, K., Thung, S., Jones, L., Deligdisch, L., & Gante, F. (1991). Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery. New England Journal of Medicine, 325, 669-674.
14. Lockwood, C., Wein, R., Lapinski, R., Casal, D., Berkowitz, G., & Alvarez, M. (1993). The presence of cervical and vaginal fetal fibronectin predicts preterm delivery in an inner-city obstetric population. American Journal of Obstetrics and Gynecology, 169, 798-804.
15. Lukes, A., Thorp, J., Eucker, B., & Panel-Short, S. (1997). Predictors of positivity for fetal fibronectin in patients with symptoms of preterm labor. American Journal of Obstetrics and Gynecology, 176, 639-641.
16. Main, D., Richardson, D., Gabbe, S., Strong, S., & Weller, S. (1987). Risk scoring for preterm labor; where do we go from here? American Journal of Obstetrics and Gynecology, 157, 789-793.
17. McGregor, J., Barret, J., & Hastings, C. (1997). Diurnal variation of salivary estriol in pregnancy. American Journal of Obstetrics and Gynecology, 176, S56.
18. McGregor, J., Heine, P., Anal, R., Dullien, V., Hastings, C., Goodwin, T., Hayashi, R., Iams, J., Robertson, P., Jackson, M., & Varner, M. (1998). Results of a prospective, blinded, multicenter trial of salivary estriol for risk of preterm labor and delivery. American Journal of Obstetrics and Gynecology, 178, S18.
19. McGregor, J., Jackson, G. M., Lachelin, G., Goodwin, T, Artal, R., Hastings, C., & Dullien, V. (1995). Salivary estriol as risk assessment for preterm labor: A prospective trial. American Journal of Obstetrics and Gynecology, 173, 1337-1342.
20. Moore, M. L., & Freda, M. C. (1998). Reducing preterm and low birthweight births: Still a nursing challenge. MCN: American Journal of Maternal Child Nursing, 23(4), 200-208.
21. Moore, M.L., Elmore, T., Ketner, M. Wagoner, S. & Walsh, K. (1995). Reduction and cessation of smoking in pregnant women: The effect of a telephone intervention. Journal of Perinatal Education, 4(1), 35-39.
22. Morrison, Jr., Albert, J., McLaughlin, B., Whitworth, N., Roberts, W., & Martin, R. (1993). Oncofetal fibronectin in patients with false labor as a predictor of preterm delivery. American Journal of Obstetrics and Gynecology, 168, 538-542.
23. Nageotte, M., Casal, D., & Senyei, A. (1994). Fetal fibronectin in patients at increased risk for premature birth. American Journal of Obstetrics and Gynecology, 170, 20-25.
24. Nageotte, M., Hollenbach, K., Vanderwahl B., & Hutch, K. (1994). Oncofetal fibronectin in patients at increased risk for preterm delivery. American Journal of Obstetrics and Gynecology, 166, 274.
25. Peaceman, A., Andrews, W., Thorp, J., Cliver, S., Lukes, A., lams, J., Coultrip, L., Eriksen, N., Holbrook, R., Elliott, J., Ingardia, C., & Pietrantoni, M. (1997). Fetal fibronectin as a predictor of preterm birth in patients with symptoms: A multicenter trial. American Journal of Obstetrics and Gynecology, 177, 13-18.